Capmatinib hydrochloride

Entry

D10891                      Drug

Name

Capmatinib hydrochloride (USAN);
Capmatinib hydrochloride hydrate (JAN);
Tabrecta (TN)

Product

TABRECTA (Novartis Pharmaceuticals Corporation)

Formula

C23H17FN6O. 2HCl. H2O

Exact mass

502.1087

Mol weight

503.3562

Structure

Simcomp

Class

Antineoplastic
DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
DG02953  AOX1 substrate

Remark

Therapeutic category:

4291

ATC code:

L01EX17

Chemical structure group:

DG02081

Product (DG02081):

D10891<JP/US>

Efficacy

Antineoplastic, Receptor tyrosine kinase inhibitor

Disease

Non-small cell lung cancer (MET exon 14 skipping positive) [DS:H00014]

Target

MET* [HSA_VAR:4233v4] [HSA:4233] [KO:K05099]

Network

N10024

Tyrosine kinase inhibitor to MET exon 14 skipping

Pathway

hsa04014

Ras signaling pathway

hsa04151

PI3K-Akt signaling pathway

hsa05200

Pathways in cancer

hsa05202

Transcriptional misregulation in cancer

hsa05223

Non-small cell lung cancer

Metabolism

Enzyme: CYP3A4 [HSA:1576], AOX1 [HSA:316]

Interaction

Brite

Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EX Other protein kinase inhibitors
     L01EX17 Capmatinib
      D10891  Capmatinib hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
  Molecular Target Inhibitors
   Capmatinib
    D10891  Capmatinib hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10891  Capmatinib hydrochloride (USAN); Capmatinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG02081  Capmatinib
     D10891  Capmatinib hydrochloride
Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG02081  Capmatinib
     D10891  Capmatinib hydrochloride
  DG02953  AOX1 substrate
   DG02081  Capmatinib
    D10891  Capmatinib hydrochloride
Target-based classification of drugs [BR:br08310]
Protein kinases
  Receptor tyrosine kinases (RTK)
   MET family
    MET* [HSA_VAR:4233v4]
     D10891  Capmatinib hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D10891
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D10891
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D10891
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
  D10891
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
  D10891
Drug groups [BR:br08330]
Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG02081  Capmatinib
Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG02081  Capmatinib
  DG02953  AOX1 substrate
   DG02081  Capmatinib

Other DBs

CAS:	1865733-40-9

PubChem:

336445209

KCF data

ATOM        34
            1   C8y C    13.3653  -15.8844
            2   C8y C    13.3653  -17.2839
            3   C8x C    14.6248  -17.9837
            4   C8x C    15.8144  -17.2839
            5   C8y C    15.8144  -15.8844
            6   C8x C    14.6248  -15.1846
            7   C8y C    17.0740  -15.1846
            8   X   F    12.1757  -15.1846
            9   C5a C    12.1757  -17.9837
            10  N1b N    10.9861  -17.2839
            11  O5a O    12.1757  -19.3832
            12  C1a C     9.7965  -17.9837
            13  N5x N    18.2636  -15.8144
            14  N4y N    19.4531  -15.1147
            15  C8y C    19.4531  -13.7152
            16  N5x N    18.2636  -13.0154
            17  C8x C    17.0740  -13.7152
            18  C8y C    20.7827  -15.6045
            19  C8x C    21.6224  -14.4149
            20  N5x N    20.7827  -13.2953
            21  C1b C    21.2025  -16.9340
            22  C8y C    22.6020  -16.9340
            23  C8x C    23.3018  -18.1936
            24  C8y C    24.7013  -18.1936
            25  C8y C    25.4010  -16.9340
            26  C8x C    24.7013  -15.7445
            27  C8x C    23.3018  -15.7445
            28  C8x C    25.4010  -19.3832
            29  C8x C    26.8006  -19.3832
            30  C8x C    27.5003  -18.1936
            31  N5x N    26.8006  -16.9340
            32  X   Cl   17.2200  -19.9500
            33  O0  O    21.9100  -19.9500
            34  X   Cl   17.2200  -19.9500
BOND        35
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     1   8 1
            9     2   9 1
            10    9  10 1
            11    9  11 2
            12   10  12 1
            13    7  13 2
            14   13  14 1
            15   14  15 1
            16   15  16 1
            17   16  17 2
            18    7  17 1
            19   14  18 1
            20   18  19 2
            21   19  20 1
            22   15  20 2
            23   18  21 1
            24   21  22 1
            25   22  23 2
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   22  27 1
            31   24  28 1
            32   28  29 2
            33   29  30 1
            34   30  31 2
            35   25  31 1
BRACKET     1    15.6100  -20.7900   15.6100  -18.8300
            1    18.4100  -18.8300   18.4100  -20.7900
            1  2
ORIGINAL  1   32
REPEAT    1   34